MedPath

PRIORIX-TETRA

PRIORIX-TETRA

Approved
DIN Number

02297884

Drug Class

Human

Market Date

Jun 4, 2008

Company
HC

GlaxoSmithKline Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02297884
AIG Number0464901001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D
A
ATC Code
J07BD54 MEASLES, COMBINATIONS WITH MUMPS, RUBELLA AND VARICELLA, LIVE ATTENUATED
Product Specifications
Dosage FormPowder For Solution
Route of AdministrationIntramuscular ,  Subcutaneous
AHFS Classification80:12.00
Health Canada Classification

ACTIVE INGREDIENTS (4)

MEASLES VIRUS VACCINE LIVE ATTENUATEDActive
Strength: 1000 CCID50 / 0.5 ML
Monograph: MEASLES VIRUS VACCINE LIVE ATTENUATED
MUMPS VIRUS VACCINE LIVE ATTENUATED (JERYL LYNN STRAIN)Active
Strength: 25118.9 CCID50 / 0.5 ML
Monograph: MUMPS VIRUS VACCINE LIVE ATTENUATED (JERYL LYNN STRAIN)
RUBELLA VIRUS VACCINE LIVE ATTENUATED (WISTAR RA27/3 STRAIN)Active
Strength: 1000 CCID50 / 0.5 ML
Monograph: RUBELLA VIRUS VACCINE LIVE ATTENUATED (WISTAR RA27/3 STRAIN)
VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA-STRAIN)Active
Strength: 1995.2623 CCID50 / 0.5 ML
Monograph: VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA-STRAIN)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.